Breast Cancer Weapons Genomics And Neoadjuvant Chemotherapy Is The 2012 Breast Cancer latest Advancement:

Public & Media --- San Antonio Breast Cancer Symposium: Press Releases

---

Barron's Medical Journal Robert Graham Ph.D. Reporting from San Antonio Breast Cancer Symposium

San Antonio Texas December 8, 2012

---

Breast Cancer Weapons Genomics And Neoadjuvant Chemotherapy Is The 2012 Breast Cancer latest Advancement:

---

San Antonio ( AP ) Genomics is a now a house hold name. Evidence have surfaced again at the San Antonio Breast Cancer Symposium. Barron's Medical Journal reports that hope for young women, those under 35, who get breast cancer out of the blue – especially because they are far more likely than older women to have a hard-to-treat type

of breast cancer called triple negative breast cancer. A chemotherapy treatment called neoadjuvant chemotherapy can actual reduce the size of large triple negative breast cancer tumors. The efficacy of neoadjuvant chemotherapy, as measured by the rate of pathological complete response (the absence of invasive and intraductal disease in the breast and the axillary lymph nodes), varies according to breast-cancer subtype. When anthracyclines, taxanes, and agents directed against anti–human. First degree relatives of Breast Cancer Patients that take a Genomic test and find

that the genes P53, P63, Her-2 and more are the largest candidates neoadjuvant chemotherapy treatments. A Houston base company called Gennxeix researcher work product. lets discuss some of their finding. Gennxeix discovered that some patients with HER2-positive breast cancer tended not respond to HER2-targeted therapies. Also, some patients with triple-negative breast cancers responded to therapies while others didn't. "We have been lumping things together that shouldn't be lumped together The new classifications - four types called HER2 "enriched," luminal A, luminal B and basal-like - categorize breast cancers by their genomic structure using a dizzying array of data points not previously available that have identified new pathways for the cancer to do its damage, making it possible for researchers to identify new places to target disease. Brought To You By Antiques of River Oaks Houston,Tx In what could be seen as the most promising development of this breast cancer study, researchers determined that some basal-like cancers had more in common with an aggressive form of ovarian cancer known as "serous" than with other types of breast cancer. Two other types of breast cancer, accounting for most cases of the disease, arise from the luminal cells that line milk ducts. These cancers have proteins on their surfaces that grab estrogen, fueling their growth. Just about everyone with estrogen-fueled cancer gets the same treatment. Some do well. Others do not. The genetic analysis divided luminal cancers into two distinct subtypes. The luminal A subtype had good prognoses while luminal B did not, suggesting that perhaps patients with luminal A tumors might do well with just hormonal therapy to block estrogen from spurring their cancers while luminal B patients might do better with chemotherapy in addition to hormonal therapy. In some cases, genetic aberrations were so strongly associated with one or the other luminal subtype that they appeared to be the actual cause of the cancer. The better News is that Genomics is on the Clock. Genomics provide a faster cheaper more effective way to detect the Her2 gene by using Semiconductor Sequencing. A example of this technique is Hybrid Pharma Gennxeix Semiconductor Sequencing. "Quantum Theory" In Action for Breast Cancer Patients. A polymerase is an enzyme whose central function is associated with polymers of nucleic acids such as RNA and DNA. The primary function of a polymerase is the polymerization of new DNA or RNA against an existing DNA or RNA template in the processes of replication and transcription. In association with a Hybrid Pharma Gennxeix also uses a Visualize Real-Time Breast Cancer Data using Signal Stochastic Resonance Units Neurons Detection and Analysis for Breast Cancer model after McCulloch-Pitts.Hybrid Pharma computer-assisted diagnosing

of breast cancer from mammograms. Hybrid Pharma works is a genetic network simulation trained with tumor incidence data from knockout experiments. Gennxeix Biotech uses Semiconductor Sequencing Chips that create a direct connection between Biochemical and digital information, bringing these two languages together. Hybrid's chips are designed like any other semiconductor chips. Pairing proprietary semiconductor technology with sequencing chemistry a nucleotide is incorporated into a strand of DNA by a polymerase, a hydrogen ion is released. Gennxeix Biotech used a high-density array of micro-machined wells for bioctechnology process in a massive way. Each well holds a different DNA template. Beneath the wells is an ion-sensitive layer and beneath that a proprietary Ion sensor. HER2 in many patients respond differently. Genomics can be the GPS to Extend life in Breast Cancer Patients. formalin fixed, paraffin embedded techniques and Her-2 Approximately Where do you really come from? And how can this information Solve Breast Cancer? Approximately 30% of malignant breast cancers demonstrate overamplification of the human epidermal receptor type 2 (HER2) gene. HER-2 can be resistant to low-doses of anthracycline-based Hybrid Pharma have demonstrated that they can be used to map DNase (deoxyribonuclease) DNA origins of replication. Hybrid Pharma Recent progress in microarray technology has been related to the development of high resolution microarrays which can map genomic alterations and constitutional variants in DNA copy number at an extremely high resolution for Breast Cancer chemotherapy. formalin fixed, paraffin embedded techniques and Her-2The Good News is that science has advanced. Sections of microarray provide targets for parallel in situ detection of DNA, RNA and protein targets in each specimen on the array. The better News is that Genomics is on the Clock. Genomics provide a faster cheaper more effective way to detect the Her2 gene by using Semiconductor Sequencing. A example of this technique is Hybrid Pharma Semiconductor Sequencing. "Quantum Theory" In Action for Breast Cancer Patients. A polymerase is an enzyme whose central function is associated with polymers of nucleic acids such as RNA and DNA. The primary function of a polymerase is the polymerization of new DNA or RNA against an existing DNA RNA template in the processes of replication and transcription. In association with a Hybrid Pharma also uses a Visualize Real-Time Breast Cancer Data using Signal Stochastic Resonance Units Neurons Detection and Analysis for Breast Cancer model after McCulloch-Pitts. Hybrid Pharma computer-assisted diagnosing of breast cancer from mammograms. Hybrid Pharma Gennxeix works is a genetic network simulation trained with tumor incidence data from knockout experiments. Gennxeix Biotech uses Semiconductor Sequencing Chips that create a direct connection between Biochemical and digital information, bringing these two languages together. Hybrid's chips are designed like any other semiconductor chips. Pairing proprietary semiconductor technology with sequencing chemistry a nucleotide is incorporated into a strand of DNA by a polymerase, a hydrogen ion is released. Gennxeix Biotech used a high-density array of micro-machined wells for bioctechnology process in a massive way. Each well holds a different DNA template. Beneath the wells is an ion-sensitive layer and beneath that a proprietary Ion sensor. HER2 in many patients response differently. Genomics is the GPS to Extend life in Breast Cancer Patients Neoadjuvant chemotherapy (NAC) induces a pathological complete response (pCR) in ~30% of patients with breast cancer. However, many patients have residual cancer after chemotherapy, which correlates with a higher risk of metastatic recurrence and poorer outcome than those who achieve a pCR. We hypothesized that molecular profiling of tumors after NAC would identify genes associated with drug resistance. Digital transcript counting was used to profile surgically resected breast cancers after NAC. Low concentrations of dual specificity

protein phosphatase 4 (DUSP4), an ERK phosphatase, correlated with high post-NAC tumor cell proliferation and with basal-like breast cancer (BLBC) status. BLBC had higher DUSP4 promoter methylation and gene expression patterns of Ras-ERK pathway activation relative to other breast cancer subtypes. DUSP4 overexpression increased chemotherapy-induced apoptosis, whereas DUSP4 depletion dampened the response to chemotherapy. Reduced DUSP4 expression in primary tumors after NAC was associated with treatment-refractory high Ki-67 scores and shorter recurrence-free survival. Finally, inhibition of mitogen-activated protein kinase kinase (MEK) synergized with docetaxel treatment in BLBC xenografts. Thus, DUSP4 downregulation activates the Ras-ERK pathway in BLBC, resulting in an attenuated response to anti-cancer chemotherapy.